What is the role of genetic testing in prostate cancer, including indications, recommended DNA‑repair gene panels, and how results affect treatment and family screening?

Genetic Testing in Prostate Cancer

All men with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays, as these tests guide the use of PARP inhibitors with proven survival benefit and inform cancer screening for patients and their families. 1

Who Should Be Tested

Metastatic Disease (Strongest Indication)

• All men with metastatic castration-resistant prostate cancer (mCRPC) should undergo genetic testing regardless of family history 1
• Men with metastatic hormone-sensitive prostate cancer should also be considered for testing to identify germline mutations for future treatment options and cascade family testing 1

Localized Disease

Men with localized prostate cancer should be tested if they meet any of the following criteria:

Syndromic Features:

• Personal history meeting criteria for hereditary breast and ovarian cancer (HBOC), hereditary prostate cancer (HPC), or Lynch syndrome (LS) 1
• Gleason ≥7 with one or more close blood relatives with ovarian cancer at any age, or breast cancer <50 years 1
• Gleason ≥7 with two or more relatives with breast, pancreatic, or prostate cancer (Gleason ≥7) at any age 1

Broader Family History:

• Two or more close blood relatives on the same side of the family with cancers in HBOC spectrum (breast, ovarian, pancreatic, prostate, melanoma) 1
• Two or more close blood relatives with cancers in Lynch syndrome spectrum (colorectal, endometrial, upper GI, ovarian, pancreatic, upper urinary tract, sebaceous adenocarcinomas) 1

Tumor Sequencing Results:

• Any man with prostate tumor sequencing showing mutations in cancer-risk genes should have confirmatory germline testing 1

Recommended Gene Panels

Core DNA Repair Genes (Highest Evidence)

For Men Meeting Syndromic Criteria:

• BRCA1/BRCA2 (97% consensus) - strongest evidence for prostate cancer risk, aggressiveness, and treatment implications 1
• HOXB13 (95% consensus) - high-grade evidence for hereditary prostate cancer 1
• DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM) (73% consensus) - moderate evidence for Lynch syndrome association 1

For Men with mCRPC (Treatment Determination):

• BRCA1/2 (88% consensus) - guides PARP inhibitor therapy 1
• ATM (62% consensus) - emerging treatment implications 1

Important Caveats About Gene Panels

• BRCA2 has the strongest evidence linking to prostate cancer risk and poor outcomes 1
• Evidence for DNA MMR genes and prostate cancer risk is moderate; consider immunohistochemistry testing of prostate tumors first to select men with greater likelihood of germline mutations 1
• ATM and NBN have emerging but not yet moderate-grade evidence for prostate cancer risk 1
• Other genes on commercial panels (CHEK2, PALB2, RAD51D, TP53) have low/insufficient data for prostate cancer risk 1

Impact on Screening

BRCA2 Mutation Carriers (80% consensus)

• Begin baseline PSA at age 40 years OR 10 years prior to youngest prostate cancer diagnosed in family (whichever comes first, but not younger than age 35) 1
• Screen yearly or as determined by baseline PSA level 1

HOXB13 Mutation Carriers (53% consensus)

• Begin baseline PSA at age 40 years OR 10 years prior to youngest prostate cancer diagnosed in family 1
• Screen yearly or as determined by baseline PSA level 1

BRCA1 Mutation Carriers

• Consider baseline PSA at age 45 years per NCCN guidelines 1

Men Testing Negative

• Follow standard NCCN prostate cancer early detection guidelines (84% consensus) 1

Impact on Treatment Decisions

Early-Stage/Localized Disease

• BRCA2 mutation status should be factored into management discussions (64% consensus) 1
• Data are emerging but not yet definitive for treatment modification in localized disease 1

High-Risk/Advanced Disease

• BRCA2 mutation status should be factored into management (97% consensus) 1
• ATM mutation status should be considered (59% consensus) 1

Metastatic Castration-Resistant Prostate Cancer

• BRCA1 (83% consensus), BRCA2 (88% consensus), and ATM (56% consensus) mutation status should guide treatment discussions 1
• PARP inhibitors (olaparib, rucaparib) have demonstrated survival benefit in mCRPC with homologous recombination repair defects 1, 2, 3
• Pembrolizumab immunotherapy is an option for DNA mismatch repair deficiency 4

Retesting Considerations

Consider repeat testing when:

• Previous results were negative or uninformative 1
• Significant change in clinical status occurs (e.g., development of metastases) 1
• Use either metastatic biopsy or circulating tumor DNA (ctDNA) when retesting 1

Family Implications

Cascade testing is critical:

• Positive germline results have screening implications for additional cancers in patients 1, 5
• Family members should undergo cascade genetic testing to identify at-risk relatives 2, 5
• This extends beyond prostate cancer to include breast, ovarian, pancreatic, and colorectal cancers depending on the gene identified 1

Common Pitfalls to Avoid

• Do not use prognostic-only genomic findings to guide treatment outside clinical trials 1
• Do not assume family history is complete or accurate - many patients have limited knowledge of relatives' cancer diagnoses 1
• Do not test only BRCA1/2 - comprehensive panels including HOXB13 and DNA MMR genes are recommended 1
• Do not skip confirmatory germline testing when tumor sequencing identifies mutations - somatic and germline mutations must be distinguished 1
• Do not delay testing in metastatic disease - results directly impact treatment selection with PARP inhibitors 1, 3